These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19890747)

  • 1. [Cost of illness and health service patterns in Morbus Parkinson in Austria].
    von Campenhausen S; Winter Y; Gasser J; Seppi K; Reese JP; Pfeiffer KP; Geiger-Gritsch S; Bötzel K; Siebert U; Oertel WH; Dodel R; Poewe W
    Wien Klin Wochenschr; 2009; 121(17-18):574-82. PubMed ID: 19890747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost of illness and its predictors for Parkinson's disease in Germany.
    Spottke AE; Reuter M; Machat O; Bornschein B; von Campenhausen S; Berger K; Koehne-Volland R; Rieke J; Simonow A; Brandstaedter D; Siebert U; Oertel WH; Ulm G; Dodel R
    Pharmacoeconomics; 2005; 23(8):817-36. PubMed ID: 16097843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs of illness in a Russian cohort of patients with Parkinson's disease.
    Winter Y; von Campenhausen S; Popov G; Reese JP; Klotsche J; Bötzel K; Gusev E; Oertel WH; Dodel R; Guekht A
    Pharmacoeconomics; 2009; 27(7):571-84. PubMed ID: 19663528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal study of the socioeconomic burden of Parkinson's disease in Germany.
    Winter Y; Balzer-Geldsetzer M; Spottke A; Reese JP; Baum E; Klotsche J; Rieke J; Simonow A; Eggert K; Oertel WH; Dodel R
    Eur J Neurol; 2010 Sep; 17(9):1156-1163. PubMed ID: 20345926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus.
    Spottke EA; Volkmann J; Lorenz D; Krack P; Smala AM; Sturm V; Gerstner A; Berger K; Hellwig D; Deuschl G; Freund HJ; Oertel WH; Dodel RC
    J Neurol; 2002 Jun; 249(6):759-66. PubMed ID: 12111311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs of Parkinson's disease in eastern Europe: a Czech cohort study.
    Winter Y; von Campenhausen S; Brozova H; Skoupa J; Reese JP; Bötzel K; Eggert K; Oertel WH; Dodel R; Ruzicka E
    Parkinsonism Relat Disord; 2010 Jan; 16(1):51-6. PubMed ID: 19665915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs of endometriosis in Austria: a survey of direct and indirect costs.
    Prast J; Oppelt P; Shamiyeh A; Shebl O; Brandes I; Haas D
    Arch Gynecol Obstet; 2013 Sep; 288(3):569-76. PubMed ID: 23503974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug and treatment costs in Parkinson's disease patients in Sweden.
    Lökk J; Borg S; Svensson J; Persson U; Ljunggren G
    Acta Neurol Scand; 2012 Feb; 125(2):142-7. PubMed ID: 21470194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct economic impact of Parkinson's disease: a research survey in the United Kingdom.
    Findley L; Aujla M; Bain PG; Baker M; Beech C; Bowman C; Holmes J; Kingdom WK; MacMahon DG; Peto V; Playfer JR
    Mov Disord; 2003 Oct; 18(10):1139-45. PubMed ID: 14534917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short- and long-term cost and utilization of health care resources in Parkinson's disease in the UK.
    Weir S; Samnaliev M; Kuo TC; Tierney TS; Walleser Autiero S; Taylor RS; Schrag A
    Mov Disord; 2018 Jul; 33(6):974-981. PubMed ID: 29603405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The current and projected economic burden of Parkinson's disease in the United States.
    Kowal SL; Dall TM; Chakrabarti R; Storm MV; Jain A
    Mov Disord; 2013 Mar; 28(3):311-8. PubMed ID: 23436720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs and quality of life of multiple sclerosis in Austria.
    Kobelt G; Berg J; Lindgren P; Plesnilla C; Baumhackl U; Berger T; Kolleger H; Vass K
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S14-23. PubMed ID: 17310339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cost of disorders of the brain in Austria in the year 2004].
    Wancata J; Sobocki P; Katschnig H;
    Wien Klin Wochenschr; 2007; 119(3-4):91-8. PubMed ID: 17347857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic burden of Parkinson's disease in a developing country: a retrospective cost analysis in Shanghai, China.
    Wang G; Cheng Q; Zheng R; Tan YY; Sun XK; Zhou HY; Ye XL; Wang Y; Wang Z; Sun BM; Chen SD
    Mov Disord; 2006 Sep; 21(9):1439-43. PubMed ID: 16773620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resource use and costs in a Swedish cohort of patients with Parkinson's disease.
    Hagell P; Nordling S; Reimer J; Grabowski M; Persson U
    Mov Disord; 2002 Nov; 17(6):1213-20. PubMed ID: 12465059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs of illness and care in Parkinson's disease: an evaluation in six countries.
    von Campenhausen S; Winter Y; Rodrigues e Silva A; Sampaio C; Ruzicka E; Barone P; Poewe W; Guekht A; Mateus C; Pfeiffer KP; Berger K; Skoupa J; Bötzel K; Geiger-Gritsch S; Siebert U; Balzer-Geldsetzer M; Oertel WH; Dodel R; Reese JP
    Eur Neuropsychopharmacol; 2011 Feb; 21(2):180-91. PubMed ID: 20888737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.
    Cruess AF; Zlateva G; Xu X; Soubrane G; Pauleikhoff D; Lotery A; Mones J; Buggage R; Schaefer C; Knight T; Goss TF
    Pharmacoeconomics; 2008; 26(1):57-73. PubMed ID: 18088159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson Symptoms and Health Related Quality of Life as Predictors of Costs: A Longitudinal Observational Study with Linear Mixed Model Analysis.
    Martinez-Martín P; Rodriguez-Blazquez C; Paz S; Forjaz MJ; Frades-Payo B; Cubo E; de Pedro-Cuesta J; Lizán L;
    PLoS One; 2015; 10(12):e0145310. PubMed ID: 26698860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The societal costs of chronic pain and its determinants: The case of Austria.
    Mayer S; Spickschen J; Stein KV; Crevenna R; Dorner TE; Simon J
    PLoS One; 2019; 14(3):e0213889. PubMed ID: 30893370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis.
    Dodel RC; Singer M; Köhne-Volland R; Szucs T; Rathay B; Scholz E; Oertel WH
    Pharmacoeconomics; 1998 Sep; 14(3):299-312. PubMed ID: 10186468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.